Inhalation

INH0426

Issue link: https://www.e-digitaleditions.com/i/1544305

Contents of this Issue

Navigation

Page 42 of 47

The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. Inhalation April 2026 41 early-stage programs while deliv- ering the speed, flexibility and quality that innovative OINDP products demand," said Sitaram Velaga, founder, president and CEO of Kenox Pharmaceuticals. CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations cations, which have demonstrated 15-20% increases in lung dose rel- ative to conventional PSD1 scale dryers. is unique relationship can enable efficient process trans- fer from R&D to GMP manu- facturing without compromising performance or risking extended timelines, a news release noted. e collaboration also can unlock opportunities for developing challenging molecules, includ- ing lipophilic, waxy and poorly aqueous-soluble APIs, as well as sensitive biologics that can be sta- bilized as dry powders. "Experic's spray-drying capabilities, aligned with our PSD-1 system, can cre- ate a seamless bridge from R&D to clinical manufacturing," said Andreas Boeckl, founder and CEO of Flurry Powders. "Together, we can enable innovators to advance complex inhalation and nasal products with greater confidence and performance." Kenox Pharmaceuticals announces clinical manufacturing readiness PRINCETON, NEW JERSEY, UNITED STATES—According to PRNewswire, Kenox Pharma- ceuticals announced it is now fully clinical manufacturing ready. e company has also expanded its GMP analytical testing capabil- ities for OINDPs, including in vitro bioequivalence (IVBE) test- ing to support advancing nasal and inhaled therapies. Kenox spe- cializes in the development and clinical manufacturing of phar- maceutical aerosol and nasal drug products, including soft mist inhalers (SMIs), dry powder inhal- ers (DPIs), nebulizers and nasal sprays. e company also sup- ports small-scale fill-finish opera- tions for small molecules, peptides and biologics, with batch sizes ranging from hundreds to a few thousand units, suitable for Phase I and Phase II clinical trials. "By integrating development, GMP testing—including IVBE—and clinical manufacturing under one roof, we [can] significantly de-risk Chiesi and Bespak expand production partnership PARMA, ITALY AND HOLMES CHAPEL, UNITED KING- DOM—Chiesi Group and Bespak announced an expansion of their long-standing partnership, increas- ing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak's Holmes Chapel site to support the next phase of Chiesi's carbon minimal inhaler (CMI) program. A company news release noted that Chiesi's CMI program is designed to significantly reduce the carbon footprint of pMDIs by up to 90%, through the transition to a next-generation, low global warming potential (GWP) pro- pellant, while maintaining estab- lished treatment options and device familiarity for patients. Reinforcing the partnership with Bespak adds industrial scale and resilience, sup- porting a phased and responsible transition. "We know that inhalers are essential treatments, and that the environmental impact associ- ated with them must be addressed without shifting the burden onto patients," said Maria Paola Chiesi, Chiesi group vice chair. "e part- nership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust." Experic and Flurry Powders form partnership CRANBURY, NEW JERSEY, UNITED STATES—Experic announced a strategic collabora- tion with Flurry Powders. Under the collaboration, Flurry can sup- port Experic's clients with special- ized spray drying, formulation development, particle engineering and analytical capabilities. A cen- tral advantage of the partnership is that Experic operates the only GMP spray dryer configured to Flurry's proprietary PSD1 specifi- ADVERTISER INDEX B Bespak 7 C Copley Scientific 3 D DDL 6 H HCmed Innovations 9 I Inhalation Sciences 11 Intertek 5 M MG America Cover 2 MSP 33 O Orbia 21 P Proveris 43 R RDD 1 S S-Matrix 45 INDUSTRY NEWS continued from page 10

Articles in this issue

Links on this page

view archives of Inhalation - INH0426